Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has approved the protocol amendment submitted ...

The company’s AI approach allows molecule candidates to be vetted for efficacy and other properties early in development.

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and ...

Changes in sleep metrics detected with wearable technology could serve as an inflammation marker and potentially predict IBD ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

Radiation therapy, once thought of mainly as a local cancer treatment, is now showing power to awaken the immune system in surprising ways. Researchers discovered that combining radiation with ...